None listed
Conditions
Interventions
Intervention1: Skin Lightening Cream: Frequency:Twice daily- morning and night. Dose:0.5 gms per application. Duration of application: 42 days
Control Intervention1: Placebo: Frequency:Twice daily- mo
Sponsors
Sami Labs
Eligibility
Inclusion criteria
Inclusion criteria: • Male and Female subjects in generally good health • Subjects of skin types III, IV, and V. • Subjects age group 18 - 55 years • Subjects willing to give a written informed consent and come for a regular follow up. • Subject willing to abide by and comply with the study protocol • Subject has not participated in a similar investigation in the past four weeks. • Subject should be willing to abstain from spa treatments/facials throughout the study period
Exclusion criteria
Exclusion criteria: • A known history or present condition of allergic response to any cosmetic products. • Subject having skin diseases (e.g. moderate to severe acne vulgaris face or nodulocystic acne, psoriasis, active atopic dermatitis, melasma, lichen planus pigmentosus/ Achy dermatosis, pigmented contact dermatitis or other cutaneous manifestations), which will interfere with the test readings. • Subjects on oral medications (e.g. steroids, anti-oxidant) which will compromise the study. • Systemic treatment which may modify the cutaneous state on the day of inclusion or in the previous 30 days, including retinoid therapy, photosensitizing drugs. • Subjects not willing to discontinue other topical fairness, anti ageing, anti wrinkle facial products. • Subjects who are pregnant, lactating or nursing. • Hypersensitivity to any component of the tested products. • History of intense sun exposure. • Chronic illness which may influence the cutaneous state. • Subject participating concurrently in any other cosmetic or therapeutic trial. • Any underlying uncontrolled medical illness such as diabetes mellitus, hypertension, liver disease or history of alcoholism, HIV, hepatitis, or any other serious medical illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a. Primary objective To assess product efficacy by overall lightening of skin tone in comparison to baseline and placebo by following parameters: â?¢ Dermatologistâ??s assessment â?¢ Instrumental measurements- mexameter, chromameter Timepoint: 6 Weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| b. Secondary objective â?¢ To assess product performance in reduction of dark spots, blemishes and marks in comparison to baseline and placebo by evaluating photographically with Imaging system - Image pro II â?¢ Assessment for adverse eventsTimepoint: 6 Weeks. | — |
Countries
India
Contacts
Public ContactDr Mukta Sachdev
MS CLINICAL RESEARCH PVT.LTD
Outcome results
None listed